Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,916 DKK | -2.87% | -3.96% | -11.11% |
Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
Apr. 16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.11% | 17.85B | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.79% | 22.02B | |
-17.84% | 20.9B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B | |
-26.18% | 8.08B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab A/S : , Seagen Get FDA Priority Review of Tisotumab Vedotin for Recurrent Cervical Cancer